Intensity-modulated proton therapy for recurrent nasopharyngeal cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study will deliver intensity-modulated proton radiotherapy to adults with biopsy-confirmed, non-metastatic recurrent nasopharyngeal carcinoma who are eligible for re-irradiation. Patients will be selected based on tumor stage (≥ T2b and/or positive nodes), ECOG performance status 0–1, and ability to tolerate treatment, and will be followed for tumor control and late radiation toxicities. The trial aims to generate higher-quality prospective evidence to compare safety, local control, and survival outcomes against historical IMRT results. Outcomes will include measures of acute and late toxicity, local progression-free survival, and overall survival.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Non-metastatic squamous cell carcinoma of the nasopharynx with biopsy confirmation, at stage ≥ T2b and/or with positive lymph nodes, (2) Pathological type WHO I-III
2. PS score (according to Eastern Cooperative Oncology Group (ECOG) standard) 0-1.

   Age ≥ 18 years.
3. Expected survival period ≥ 6 months
4. Before treatment, evaluate the tumor range and size of the patient.
5. Nutritional and general physical condition must be able to tolerate the recommended radiotherapy and chemotherapy.

Exclusion Criteria:

1. Evidence of distant metastasis in stage IVc
2. Patients with isolated recurrence of cervical lymph nodes;
3. Patients have participated in other interventional trials for tumors
4. Having suffered from other malignant tumors within 5 years (excluding melanoma skin cancer) or tumors originating from the head and neck region Untreated active infections

Where it's running

• Guangzhou Concord Cancer Center
  Guangzhou, Guangdong, China Recruiting
• Guangzhou concord cancer center
  Guanzhou, Guangzhou, China Recruiting

Study contacts

• Study coordinator: Taize Yuan, M.D., Ph.D.
• Email: taize.yuan@ccm.cn
• Phone: 8620-32506195

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Comparing neoadjuvant and adjuvant therapies for recurrent nasopharyngeal carcinoma

  This study is testing whether giving treatment before surgery or after surgery helps people with recurrent nasopharyngeal cancer do better.

  Recruiting at 2 sites Phase 3 Eye & ENT Hospital of Fudan University · Shanghai, Shanghai Municipality and 6 other locations · NCT06235203

• Comparing adjuvant therapy to surgery alone for early-stage recurrent nasopharyngeal carcinoma

  This study is testing if adding chemotherapy and immunotherapy after surgery helps people with early-stage recurrent nasopharyngeal carcinoma do better than just having surgery alone.

  Recruiting at 3 sites Phase 3 Eye & ENT Hospital of Fudan University · Shanghai, Shanghai Municipality and 6 other locations · NCT06228079

• Adding a new drug to immunotherapy for advanced nasopharyngeal cancer

  This study is testing if adding a new drug to standard immunotherapy can help people with advanced nasopharyngeal cancer live longer and feel better after their initial treatment.

  Recruiting at 83 sites Phase 2 National Cancer Institute (NCI) · Dublin, California and 94 other locations · NCT06029270

• Low-temperature plasma radiofrequency ablation versus high-frequency electrocautery resection for localized recurrent nasopharyngeal carcinoma

  This trial will see if low-temperature plasma radiofrequency ablation works better than high-frequency electrocautery resection for adults with localized recurrent nasopharyngeal carcinoma.

  Recruiting at 3 sites Sun Yat-sen University · Guangzhou, Guangdong and 2 other locations · NCT04425265

• Using Toripalimab with Chemoradiotherapy for Recurrent Nasopharyngeal Carcinoma

  This study is testing if adding a new drug called Toripalimab to standard chemotherapy and radiation can help people with recurrent nasopharyngeal cancer live longer and feel better during treatment.

  Recruiting Phase 3 Cancer Hospital of Guangxi Medical University · Nanning, Guangxi · NCT04376866

• Combining PD-1 antibody with chemoradiotherapy for recurrent nasopharyngeal carcinoma

  This study is testing if adding a PD-1 antibody to standard chemoradiotherapy can help people with recurrent nasopharyngeal carcinoma feel better compared to just using chemoradiotherapy alone.

  Recruiting at 5 sites Phase 3 Sun Yat-sen University · Guangzhou, Guangdong and 11 other locations · NCT03907826

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.